A 1-year, international, multicenter, randomized, double-blind, parallel-group, placebo-controlled phase IV study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either quetiapine fumarate IR (SEROQUEL) or placebo.
Study identifier:D1441C00131
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 1-year, international, multicenter, randomized, double-blind, parallel-group, placebo-controlled phase IV study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either quetiapine fumarate IR (SEROQUEL) or placebo.
Medical condition
schizophrenia
Phase
Phase 4
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
-
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
